Three CooperCompanies directors just put $1.33 million of their own money into COO near $53–$54. Add record $273M free cash flow, an expanded $3B buyback authorization and an 11.1× forward P/E—and this beaten-down medtech stock deserves a much closer look. 👁️

Read entire article

Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.

Read entire article

Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?

Read entire article

Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?

Read entire article

Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.

Read entire article

Is Occidental Petroleum one of the market's most misunderstood value stocks? With Warren Buffett owning more than a quarter of the company, a brand-new CEO buying shares, $7.1 billion of debt retired, and a carbon-capture business quietly emerging, OXY may be much more than just another oil producer.

Read entire article

CarMax isn't a flashy AI stock—but it may be one of the more interesting turnaround stories in today's market. New CEO Keith Barr just invested nearly $500,000 of his own money, institutions control over 112% of the float, and valuation appears unusually attractive on a PEG basis. Here's why we think investors should take a closer look.

Read entire article

After falling more than 80% from its peak, VF Corporation is quietly rebuilding. Insider buying, strong free cash flow, rapid deleveraging, and a 0.40 PEG ratio suggest the owner of The North Face, Vans, and Timberland may finally be finding its footing.

Read entire article

Norwegian Cruise Line (NCLH) may be one of the market’s most misunderstood recovery plays. Despite heavy debt concerns and softer guidance, insiders are buying aggressively, institutions still dominate ownership, and the stock trades at surprisingly cheap valuation levels relative to long-term earnings potential.

Read entire article

AECOM (NYSE: ACM) may be one of the most misunderstood infrastructure stocks in the market. With a record $26.2 billion backlog, insider buying from top executives, and a surprisingly cheap valuation, this engineering and consulting powerhouse could be quietly laying the foundation for substantial long-term upside.

Read entire article